Pure Global

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers - Trial NCT06402136

Access comprehensive clinical trial information for NCT06402136 through Pure Global AI's free database. This Phase 1 trial is sponsored by Traws Pharma, Inc. and is currently Recruiting. The study focuses on Healthy Volunteers Only. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06402136
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06402136
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered 83-0060 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers

Study Focus

Healthy Volunteers Only

83-0060

Interventional

drug

Sponsor & Location

Traws Pharma, Inc.

Sydney, Australia

Timeline & Enrollment

Phase 1

Apr 15, 2024

Sep 01, 2024

64 participants

Primary Outcome

Plasma concentration

Summary

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary
 efficacy of 83-0060 in Healthy Volunteers

ICD-10 Classifications

Healthy person accompanying sick person
Routine general health check-up of armed forces
Routine general health check-up of sports teams

Data Source

ClinicalTrials.gov

NCT06402136

Non-Device Trial